Ravi Talati, DO
Pediatric Hematology-Oncology · Cleveland, OHNPI 1619233228
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,393 of the $24,373 with a category attached, or 63.2%. 6 manufacturers reported payments, led by Pfizer at 40.5% of the total.
Across 32 payments — averaging $761.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$10K
- Sanofi$8K
- Sobi, Inc$4K
- Global Blood Therapeutics, Inc.$2K
- Agios Pharmaceuticals, Inc.$340
- Novo Nordisk$125
Across 7 payments — averaging $5705.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Agios Pharmaceuticals, Inc.$39K
- Pfizer$888
What the payments were for
- Consulting fees$15,39363%
- Speaking & faculty fees$4,16717%
- Travel & lodging$3,81416%
- Food & beverage$9994%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 12 | $9,861 |
| Sanofi | 7 | $8,233 |
| Sobi, Inc | 3 | $4,019 |
| Global Blood Therapeutics, Inc. | 2 | $1,795 |
| Agios Pharmaceuticals, Inc. | 7 | $340 |
| Novo Nordisk | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,373 in reported general payments places this provider in the 85th percentile of 143 pediatric hematology-oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 20 | $149 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Cleveland
- Rabi HannaCleveland$123K
- Harry Layton LesmanaCleveland$16K
- Matteo TruccoCleveland$11K
- Duncan StearnsCleveland$11K
- Stacey ZahlerCleveland$10K
- Eric KodishCleveland$9K
- Mari DallasCleveland$5K
- Irina PatevaCleveland$3K
- Michael KellyCleveland$3K
- Aashima PandhiCleveland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.